Chinese patients with gastric cancer need targeted adjuvant chemotherapy schemes

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 10, 2012, Pages 5263-5272

  Shi, Wen Tao ^a   Wei, Lei ^a   Xiang, Jin ^a,b   Su, Ke ^a   Ding, Qiong ^a   Tang, Meng Jie ^a   Li, Ji Qiang ^a   Guo, Yi ^b   Wang, Pu ^a   Zhang, Jing Wei ^a  

^a WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Adjuvant chemotherapy; Gastric cancer; Quality assessment; Regional scheme

Indexed keywords

EID: 84874001241     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.10.5263     Document Type: Article

References (55)

1. Ajani JA, Rodriguez W, Bodoky G, et al (2010). Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol, 28, 1547-53.
2. Al-Batran SE, Hartmann JT, Probst S, et al (2008). Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol, 26, 1435-42.
3. Allum WH, Hallissey MT, Kelly KA (1989a). Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet, 1, 571-4.
4. Allum WH, Hallissey MT, Ward LC, Hockey MS (1989b). A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group. Br J Cancer, 60, 739-44.
5. Bajetta E, Buzzoni R, Mariani L, et al (2002). Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol, 13, 299-307.
6. Bonenkamp JJ, Hermans J, Sasako M, et al (1999). Extended lymph-node dissection for gastric cancer. N Engl J Med, 340, 908-14.
7. Bonfani G (1988). Adjuvant treatments following curative resection for gastric cancer. Br J Surg, 75, 1100-4.
8. Bouche O, Ychou M, Burtin P, et al (2005). Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol, 16, 1488-97.
9. Chen Z. Report of the third national mortality retrospective sampling survey. Beijing: Peking Union Medical College Press; 2008.
10. Chipponi J, Huguier M, Pezet D, et al ,2004, Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer, Am J Surg, 187, 440-5
11. Cirera L, Balil A, Batiste-Alentorn E, et al (1999). Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol, 17, 3810-5.
12. Coombes RC, Schein PS, Chilvers CE, et al (1990). A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol, 8, 1362-9.
13. Cuschieri A, Weeden S, Fielding J, et al (1999). Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer, 79, 1522-30.
14. De Vita F, Giuliani F, Orditura M, et al (2007). Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol, 18, 1354-8.
15. Di Costanzo F, Gasperoni S, Manzione L, et al (2008). Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst, 100, 388-98.
16. Douglass HO Jr. (1982). Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group. Cancer, 49, 1116-22.
17. Engstrom PF, Lavin PT, Douglass HO, Jr., Brunner KW (1985). Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Cooperative Oncology Group study (EST 3275). Cancer, 55, 1868-73.
18. Estape J, Grau JJ, Lcobendas F, et al (1991). Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann Surg, 213, 219-21.
19. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T (1999). Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer, 85, 529-34.
20. Grau JJ, Estape J, Alcobendas F, Pera C, Daniels M, Teres J (1993). Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer, 29A, 340-2.
21. Guyatt G, Oxman AD, Akl EA, et al (2011a). GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol, 64, 383-94.
22. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A (2011b). GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol, 64, 380-2.
23. Hallissey MT, Dunn JA, Ward LC, Allum WH (1994). The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet, 343, 1309-12.
24. Hamazoe R, Maeta M, Kaibara N (1994). Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer, 73, 2048-52.
25. Hartgrink HH, van de Velde CJ, Putter H, et al (2004). Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol, 30 ,643-9.
26. Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) 2011.
27. Kang YK, Kang WK, Shin DB, et al (2009). Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol, 20, 666-73.
28. Kobayakawa M, Kojima Y (2011). Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. Onco Targets Ther, 4, 193-201.
29. Krook JE, O'Connell MJ, Wieand HS, et al (1991). A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer, 67, 2454-8.
30. Kulig J, Kolodziejczyk P, Sierzega M, et al (2010). Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology, 78, 54-61.
31. Li DZ, Zhao YT, Song Z (2009). Effects of FOLFOX4 neoadjuvant chemotherapy protocol on advanced gastric cancer. J Xinxiang Med College, 26, 170-2.
32. Lise M, Nitti D, Marchet A, et al (1995). Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol, 13, 2757-63.
33. Macdonald JS, Fleming TR, Peterson RF, et al (1995). Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol, 2, 488-94.
34. Nakajima T, Fukami A, Takagi K, Kajitani T (1980). Adjuvant chemotherapy with mitomycin C, and with a multi-drug combination of mitomycin C, 5-fluorouracil and cytosine arabinoside after curative resection of gastric cancer. Jap J Clin Oncol, 10, 187.
35. Nakajima T, Takahashi T, Takagi K, Kuno K, Kajitani T (1984). Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol, 2, 1366-71.
36. Nakajima T, Nashimoto A, Kitamura M, et al (1999). Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet, 354, 273-7.
37. Nakajima T, Kinoshita T, Nashimoto A, et al (2007). Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg, 94, 1468-76.
38. Nashimoto A, Nakajima T, Furukawa H, et al (2003). Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol, 21, 2282-7.
39. Neri B, Cini G, Andreoli F, et al (2001). Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer, 84, 878-80.
40. Nitti D, Wils J, Dos Santos JG, et al (2006). Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol, 17, 262-9.
41. Panzini I, Gianni L, Fattori PP, et al (2002). Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori, 88, 21-7.
42. Paoletti X, Oba K, Burzykowski T, et al (2010). Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA, 303, 1729-37.
43. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.
44. Sakuramoto S, Sasako M, Yamaguchi T, et al (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med, 357, 1810-20.
45. Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R (1994). Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol, 12, 970-4.
46. Schlag P (1987). Adjuvant chemotherapy in gastric cancer. World J Surg, 11, 473-7.
47. Scott NW, McPherson GC, Ramsay CR, Campbell MK (2002). The method of minimization for allocation to clinical trials. a review. Control Clin Trials, 23, 662-74.
48. Takahashi T, Hagiwara A, Shimotsuma M, Sawai K, Yamaguchi T (1995). Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. World J Surg, 19, 565-9.
49. Tentes AA, Markakidis SK, Karanikiotis C, et al (2006). Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer. Langenbecks Arch Surg, 391, 124-9.
50. Tsavaris N, Tentas K, Kosmidis P, et al (1996). A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemotherapy, 42, 220-6.
51. Yang Y, Xu Q, Huang YN, Yang SJ, Du P (2010). Clinical study of intraperitoneal injection of sapylin combined with intraperitoneal hyperchemic hypo-osmolar infusion during radical gastrectomy. Mod Oncol, 18, 1340-2.
52. Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH (2001). Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg, 25, 985-90.
53. Zhang YQ, Xu HM (2005). Analysis and evaluation for the effect of postoperative introperitoneal chemotherapy in gastric cancer. Chin J Clin Oncol, 32, 38-41.
54. Zhou JW, Zhou Y, Luo ZF, et al (2011). Adjuvant chemotherapy of teniposide combined with oxaliplatin and 5-fluorouracil for resected gastric carcinoma. J Chin Pract Diagn Ther, 25, 641-3.
55. Zhou XN, Sun XB, Chen WQ, et al (2012). Analysis of incidence and mortality of stomach cancer in China from 2003 to 2007. Tumor, 32, 109-14.